Cardior Pharmaceuticals

Executive Summary

Cardior Pharmaceuticals is a German clinical-stage biopharmaceutical company pioneering RNA-based therapeutics for heart diseases. Founded in 2016, the company leverages deep expertise in non-coding RNA biology to address root causes of cardiac dysfunction. Its lead candidate, CDR132L, is a first-in-class therapy targeting pathological cardiac remodeling following myocardial infarction, with a novel mechanism that inhibits microRNA-132. CDR132L has demonstrated favorable safety and efficacy signals in Phase 1b, and a Phase 2 trial (HF-REVERT) in post-MI patients with left ventricular dysfunction is ongoing. The company’s platform has potential to expand into other cardiovascular indications. Cardior is privately held and has attracted significant investor interest due to its innovative approach in a high-unmet-need area.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 HF-REVERT top-line data for CDR132L60% success
• H1 2027Potential strategic partnership or licensing deal for CDR132L ex-Europe rights40% success
• Q2 2027IND filing for next-generation candidate in heart failure with preserved ejection fraction (HFpEF)50% success